{"id":"fluoropyrimidine-plus-leucovorin","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fluoropyrimidines, such as 5-fluorouracil, work by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis. Leucovorin, also known as folinic acid, is a form of folic acid that helps to stabilize the enzyme and increase the effectiveness of the fluoropyrimidine.","oneSentence":"Inhibits thymidylate synthase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:06.836Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Breast cancer"},{"name":"Stomach cancer"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT03301454","phase":"PHASE2","title":"Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2018-08-20","conditions":"Esophageal Cancer, Squamous Cell","enrollment":15},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT04230187","phase":"PHASE3","title":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-09-01","conditions":"Colorectal Cancer","enrollment":528},{"nctId":"NCT05677490","phase":"PHASE3","title":"mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-01-31","conditions":"Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":382},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT07334587","phase":"NA","title":"Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Allama Iqbal Medical College","startDate":"2025-09-01","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":248},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT06841679","phase":"PHASE2, PHASE3","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":778},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT02872116","phase":"PHASE3","title":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-10-12","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma","enrollment":2031},{"nctId":"NCT03584711","phase":"PHASE2","title":"FOLFOX + Panitumumab According to a \"Stop and go\" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-26","conditions":"Metastatic Colorectal Cancer","enrollment":118},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT02896907","phase":"EARLY_PHASE1","title":"Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2016-10-18","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":8},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT06475352","phase":"PHASE2","title":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-20","conditions":"Digestive Cancer, Colorectal Cancer","enrollment":400},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT00807911","phase":"PHASE2","title":"Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-11-01","conditions":"Rectal Cancer","enrollment":322},{"nctId":"NCT06275958","phase":"PHASE3","title":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-07-01","conditions":"Older Patients, Colorectal Cancer, Metastatic Cancer","enrollment":587},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT06253650","phase":"PHASE2","title":"Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-01","conditions":"Gastric Cancer, HER2-positive Gastric Cancer","enrollment":46},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT04034459","phase":"PHASE2","title":"FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-11-25","conditions":"Metastatic Colorectal Cancer","enrollment":109},{"nctId":"NCT04310176","phase":"PHASE2","title":"Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-05-24","conditions":"Ras-mutated Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT02625610","phase":"PHASE3","title":"Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-12-24","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction","enrollment":499},{"nctId":"NCT01896531","phase":"PHASE2","title":"A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-08-14","conditions":"Gastric Cancer","enrollment":153},{"nctId":"NCT01362374","phase":"PHASE1","title":"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-07-11","conditions":"Neoplasms","enrollment":122},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT04418895","phase":"PHASE2","title":"Neoadjuvant Therapy for Localized Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-08-13","conditions":"Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT04188145","phase":"PHASE3","title":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-27","conditions":"Metastatic Colorectal Cancer","enrollment":400},{"nctId":"NCT02270606","phase":"PHASE1","title":"Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2014-12-04","conditions":"Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum","enrollment":14},{"nctId":"NCT02167321","phase":"PHASE2","title":"Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2014-12","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT03368859","phase":"PHASE2","title":"A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab","status":"TERMINATED","sponsor":"AbbVie","startDate":"2018-03-20","conditions":"Cancer","enrollment":70},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT02114359","phase":"PHASE3","title":"Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-02","conditions":"Gastric Cancer","enrollment":111},{"nctId":"NCT03515941","phase":"EARLY_PHASE1","title":"Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers","status":"TERMINATED","sponsor":"Tannaz Armaghany","startDate":"2018-06-22","conditions":"Gastrointestinal Cancer","enrollment":6},{"nctId":"NCT03300609","phase":"PHASE3","title":"5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2018-02-27","conditions":"Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7","enrollment":4},{"nctId":"NCT04397601","phase":"","title":"Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2020-05-11","conditions":"Metastatic Colorectal Cancer","enrollment":220},{"nctId":"NCT00976768","phase":"PHASE2","title":"Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2004-10","conditions":"Advanced Gastric Cancer","enrollment":44},{"nctId":"NCT01183780","phase":"PHASE3","title":"A Study in Second Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12-02","conditions":"Colorectal Cancer","enrollment":1072},{"nctId":"NCT01479465","phase":"PHASE2","title":"Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Colorectal Cancer","enrollment":266},{"nctId":"NCT03668418","phase":"","title":"Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2018-06-01","conditions":"Liver Cancer, Pancreatic Cancer, Gastric Cancer","enrollment":120},{"nctId":"NCT00500292","phase":"PHASE2","title":"A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-03","conditions":"Colorectal, Cancer","enrollment":109},{"nctId":"NCT03389659","phase":"PHASE3","title":"XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02","conditions":"Vitamin D3","enrollment":750},{"nctId":"NCT01279681","phase":"PHASE3","title":"Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2011-01","conditions":"Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity","enrollment":32},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT01286818","phase":"PHASE1","title":"A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Colorectal Carcinoma","enrollment":6},{"nctId":"NCT00062426","phase":"PHASE3","title":"Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Prologue Research International","startDate":"2003-05","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00182715","phase":"PHASE3","title":"Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Velindre NHS Trust","startDate":"2005-03","conditions":"Colorectal Cancer","enrollment":2421},{"nctId":"NCT01786538","phase":"PHASE3","title":"Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines","status":"WITHDRAWN","sponsor":"Asan Medical Center","startDate":"2013-06","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT00889343","phase":"PHASE2","title":"Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2009-03","conditions":"Colorectal Neoplasms","enrollment":101},{"nctId":"NCT00482222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2007-02","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":340},{"nctId":"NCT00101686","phase":"PHASE3","title":"Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Colorectal Neoplasms","enrollment":547},{"nctId":"NCT00524706","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Shizuoka Cancer Center","startDate":"2007-08","conditions":"Colorectal Cancer","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeloda"],"phase":"phase_2","status":"active","brandName":"Fluoropyrimidine plus leucovorin","genericName":"Fluoropyrimidine plus leucovorin","companyName":"Seattle Project Corporation","companyId":"seattle-project-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits thymidylate synthase Used for Colorectal cancer, Breast cancer, Stomach cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}